Clinical trial · Observational
PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Combination of Immune Checkpoint Inhibitors PD-1 Monoclonal Antibody and Radiotherapy for Recurrent, Metastatic and Persistent Advanced Cervical Cancer: A Retrospective Cohort Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to investigate retrospectively the effects of combination of immune checkpoint inhibitors anti-programmed death-1 antibody (PD-1 antibody) and radiotherapy for recurrent, metastatic and persistent advanced cervical carcinomas. Patients may or may not accept PD-1 antibody as maintenance therapy. Patients are followed up and the survival outcomes are evaluated. The primary endpoint are objective remission rate. The secondary endpoints are progression-free survival, overall survival and severe adverse events.
Conditions
Conditions (10)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anti-programmed Death-1 Antibody | — | UNRESOLVED | — |
| Immune Checkpoint Inhibitors | — | UNRESOLVED | — |
| Metastatic Cervical Carcinoma | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Objective Remission Rate | — | UNRESOLVED | — |
| Overall Survival | — | UNRESOLVED | — |
| Persistent Advanced Cervical Carcinoma | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Progression-free Survival | — | UNRESOLVED | — |
| Radiotherapy | — | UNRESOLVED | — |
| Recurrent Cervical Carcinoma | Cervical Carcinoma | CURATED_BROADER | 0.78 |
| Severe Adverse Events | — | UNRESOLVED |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy for targeted lesions and PD-1 antibody | Combination Product | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Objective remission rate
- timeFrame
- One year
- description
- Objective remission rate in one month after the end of radiotherapy
Secondary outcomes (3)
- measure
- Progression-free survival
- timeFrame
- One year
- description
- Progression-free survival after the end of radiotherapy
- measure
- Overall survival
- timeFrame
- One year
- description
- Overall survival after the end of radiotherapy
- measure
- Severe adverse events
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 18 years or older * Confirmed of recurrent, metastatic, and persistent advanced cervical cancer * Confirmed of subtypes of cervical squamous carcinoma, adenocarcinoma and adenosquamous carcinoma * Accepting radiotherapy with concurrent anti PD-1 therapy * With detailed follow-up outcomes Exclusion Criteria: \- Not meeting all of the inclusion criteria
References
Publications (0)
Data not yet available